Sensitivity of disease parameters to flexible budesonide/formoterol treatment in an allergic rat model

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 1, 2009, Pages 20-26

  Brange, Charlotte ^a   Smailagic, Amir ^a   Jansson, Anne Helene ^a   Middleton, Brian ^b   Miller Larsson, Anna ^a   Taylor, John D ^a   Silberstein, David S ^b   Lal, Harbans ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Adjustable dosing; Budesonide; Dose response; ELGV; Flexible dosing; Formoterol; Lung oedema; Maintenance and reliever therapy; Maintenance dosing; Rat

Indexed keywords

ALLERGEN; BUDESONIDE PLUS FORMOTEROL; METHACHOLINE; OVALBUMIN;

AIRWAY; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; EDEMA; EXCISION; GAS; LUNG; LUNG WEIGHT; MALE; NONHUMAN; PARAMETER; PNEUMONIA; PRIORITY JOURNAL; RAT; SENSITIZATION;

ANIMALS; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; BUDESONIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ETHANOLAMINES; LUNG; MALE; ORGAN SIZE; OVALBUMIN; RATS; RATS, INBRED BN; TIME FACTORS;

EID: 58349099434     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.10.011     Document Type: Article

References (29)

1. Fitzgerald J.M., Sears M.R., Boulet L.-P., Becker A.B., McIvor A.R., Ernst P., et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 10 (2003) 427-434
2. Vogelmeier C., D'Urzo A., Jaspal M., Merino J.M., Johansson G., and Boutet S. Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real-life study. Proc Am Thorac Soc 2 (2005) A628
3. Kuna P., Peters M.J., Manjra A.I., Jorup C., Naya I.P., Martínez-Jimenez N.E., et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 61 (2007) 725-736
4. Pauluhn J., and Ulrich M. Experimental approaches to evaluate respiratory allergy in animal models. Exp Toxicol Pathol 56 (2005) 203-234
5. Brange C., Smailagic A., Jansson A.H., Eriksson C., and Wang X.D. Effects of intermittent therapy with budesonide/formoterol combination on airway hyperresponsiveness and inflammation in an allergic rat model. In: Abstract Book XXIII EAACI Congress (2004) 218 Abs 722
6. Brange C., Smailagic A., Eriksson C., and Wang X.D. Effects of budesonide/formoterol maintenance therapy on airway hyperresponsiveness and inflammation in an allergic rat model. Eur Respir J 24 suppl 48 (2004) 351s
7. Jansson A.-H., Eriksson C., and Wang X.D. Lung inflammatory responses and hyperinflation induced by an intratrachael exposure to lipopolysaccharide in rats. Lung 182 (2004) 163-171
8. Stengel P.W., Yiamouyiannis C.A., Obenchain R.L., Cockerham S.L., and Silbaugh S.A. Methacholine-induced pulmonary gas trapping in guinea pigs, hamsters, mice, and rats. J Appl Physiol 79 (1995) 2148-2153
9. Jansson A.-H., Smailagic A., Dutius Andersson A.-M., Zackrisson C., Fehniger T.E., Stevens T.R., et al. Evaluation of excised lung gas volume measurements in animals with genetic or induced emphysema. Respir Physiol Neurobiol 150 (2006) 240-250
10. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group. New Eng J Med 337 (1997) 1405-1411
11. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
12. Sears M.R., Boulet L.-P., Laviolette M., Fitzgerald J.M., Bai T.R., Kaplan A., et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 31 (2008) 982-989
13. Kamachi A., Nasuhara Y., Nishimura M., Takahashi T., Homma Y., Ohtsuka Y., et al. Dissociation between airway responsiveness to methacholine and responsiveness to antigen. Eur Respir J 19 (2002) 76-83
14. Zosky G., von Garnier C., Stumbles P., Holt P., Sly P., and Turner D. The pattern of methacholine responsiveness in mice is dependent on antigen challenge dose. Respir Res 5 (2004) 15
15. Hylkema M.N., Hoekstra M.O., Luinge M., and Timens W. The strength of the OVA-induced airway inflammation in rats is strain dependent. Clin Exp Immunol 129 (2002) 390-396
16. Fernandes D.J., Mitchell R.W., Lakser O., Dowell M., Stewart A.G., and Solway J. Do inflammatory mediators influence the contribution of airway smooth muscle contraction to airway hyperresponsiveness in asthma?. J Appl Physiol 95 (2003) 844-853
17. Huang T.-J., Eynott P., Salmon M., Nicklin P.L., and Chung K.F. Effect of topical immunomodulators on acute allergic inflammation and bronchial hyperresponsiveness in sensitised rats. Eur J Pharmacol 437 (2002) 187-194
18. Xu L., Olivenstein R., Martin J.G., and Powell W.S. Inhaled budesonide inhibits OVA-induced airway narrowing, inflammation, and cys-LT synthesis in BN rats. J Appl Physiol 89 (2000) 1852-1858
19. Besse J.C., and Bass A.D. Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J Pharmacol Exp Ther 154 (1966) 224-238
20. Eickelberg O., Roth M., Lorx R., Bruce V., Rudiger J., Johnson M., et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274 (1999) 1005-1010
21. Samuelson W.M., and Davies A.O. Hydrocortisone-induced reversal of beta-adrenergic receptor uncoupling. Am Rev Respir Dis 130 (1984) 1023-1026
22. Roth M., Johnson P.R., Rudiger J.J., King G.G., Ge Q., Burgess J.K., et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360 (2002) 1293-1299
23. Mak J.C.W., Nishikawa M., Shirasaki H., Miyayasu K., and Barnes P.J. Protective effects of a glucocorticoid on downregulation of pulmonary beta2-adrenergic receptors in vivo. J Clin Invest 96 (1995) 99-106
24. Baraniuk J., Ali M., Brody D., Maniscalco J., Gaumond E., Fitzgerald T., et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 155 (1997) 704-710
25. Kaur M., Chivers J.E., Giembycz M.A., and Newton R. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 73 (2008) 203-214
26. Moore P.E., Laporte J.D., Gonzalez S., Moller W., Heyder J., Panettieri Jr. R.A., et al. Glucocorticoids ablate IL-1beta-induced beta-adrenergic hyperresponsiveness in human airway smooth muscle cells. Am J Physiol 277 (1999) L932-L942
27. Tan K.S., Grove A., McLean A., Gnosspelius Y., Hall I.P., and Lipworth B.J. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 156 (1997) 28-35
28. Aziz I., and Lipworth B.J. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. Chest 115 (1999) 623-628
29. Miller-Larsson A., and Selroos O. Steroid sparing strategies. Long acting inhaled β2-agonists. In: Adcock I.M., and Chung K.F. (Eds). Overcoming steroid insensitivity in respiratory disease (2008), John Wiley & Sons, Ltd 163-85